View in EDS

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.

Saved in:
Bibliographic Details
Title: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Authors: Sharma P; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Kanapuru B; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., George B; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Lin X; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Xu Z; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Bryan WW; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Pazdur R; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 May 02; Vol. 28 (9), pp. 1759-1764.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35046063
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sharma+P%22">Sharma P</searchLink>; Center for Biologics Evaluation and Research, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Kanapuru+B%22">Kanapuru B</searchLink>; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22George+B%22">George B</searchLink>; Center for Biologics Evaluation and Research, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Lin+X%22">Lin X</searchLink>; Center for Biologics Evaluation and Research, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Xu+Z%22">Xu Z</searchLink>; Center for Biologics Evaluation and Research, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Bryan+WW%22">Bryan WW</searchLink>; Center for Biologics Evaluation and Research, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Pazdur+R%22">Pazdur R</searchLink>; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.<br /><searchLink fieldCode="AU" term="%22Theoret+MR%22">Theoret MR</searchLink>; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2022 May 02; Vol. 28 (9), pp. 1759-1764.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35046063
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-21-3803
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1759
    Titles:
      – TitleFull: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sharma P
      – PersonEntity:
          Name:
            NameFull: Kanapuru B
      – PersonEntity:
          Name:
            NameFull: George B
      – PersonEntity:
          Name:
            NameFull: Lin X
      – PersonEntity:
          Name:
            NameFull: Xu Z
      – PersonEntity:
          Name:
            NameFull: Bryan WW
      – PersonEntity:
          Name:
            NameFull: Pazdur R
      – PersonEntity:
          Name:
            NameFull: Theoret MR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: 2022 May 02
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1